First human test of experimental COVID-19 inflammation drug
Disease control
Completed
This completed early-stage study tested whether an experimental drug called SIR1-365 is safe for hospitalized patients with severe COVID-19. Researchers enrolled 45 adults to receive either the drug or a placebo for 14 days, monitoring side effects and whether it helped reduce in…
Phase: PHASE1 • Sponsor: Sironax USA, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC